UNASSIGNED: 5107 Background: Though CCRT is now recommended in LACC, there is no standard regime. We review our experience with use of weekly @entity900 concurrent with @entity1161 ( @entity1161 ) during a three-year period. METHODS: All @entity1 with LACC treated by CCRT reviewed. Demographic details, symptomatology, staging (AJCC), management, and outcome data collected. All @entity1 had external beam @entity1161 (EBRT) 4500 cGy + boost 540 cGy in 28 fractions followed by single application brachytherapy with @entity5166 , delivering 3000 cGy to point A + parametrial boost. Chemotherapy: @entity900 40 mg/m(2) (30 mg/m(2) if para aortic nodes included in @entity1161 ) weekly for 5 doses starting with @entity1161 . RESULTS: Between 1998-2000, 33 @entity1 with median age 47 (range 23-69) treated. Median menarche age 12 (range 11-16), menopausal status: 16 pre, 1 peri, and 16 post. Obstetric history: Multiparity common, median pregnancies 8 (range 2-15), median age first pregnancy 17 (range 14-26). All but 2 presented with @entity3556 , 14 with @entity2371 , 5 with vaginal discharge. Median symptom duration 6 months. Diagnosis by punch biopsy all @entity1 with 32 @entity957 , 1 poorly differentiated @entity189 . Histologic grade 2 in 18 @entity1 , 3 in 13, and unspecified 2. Stage IB2:3, IIB:17, IIIB:11, @entity3480 : 2. All @entity1 had normal baseline blood count and renal function. EBRT given to pelvis alone in 23, pelvis + paraaortic nodes in 10. Three interruptions during therapy, 14 short delays. Brachytherapy in 24 @entity1 . Chemotherapy 11 delays, 3 dose reductions. Cycles: 22 had 5, 7 had 4, and 4 had 3. Of 33 @entity1 , 27 (82%) achieved complete remission, 6 had persistent disease. No grade 3 or 4 hematologic/ @entity8 . Ten relapsed -4 locally, 3 distant, 3 both. With median follow up of 21 months (range 4-40), 23 disease free, 6 with active disease, 4 dead due to disease progression. CONCLUSION: CCRT with weekly @entity900 is a well tolerated regime, easy to administer in ambulatory care setting, and results appearpromising. More @entity1 are being recruited. No significant financial relationships to disclose.

Concurrent chemoradiation therapy (CCRT) with weekly XXXX in locally advanced cancer cervix (LACC): Single institution experience.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal toxicity'] @entity3556 :: ('MESH:D014592', 'Disease') :: ['vaginal bleeding'] @entity3480 :: ('MESH:C538167', 'Disease') :: ['IVA'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2371 :: ('MESH:D017699', 'Disease') :: ['pelvic pain'] @entity5166 :: ('MESH:D002586', 'Chemical') :: ['cesium'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']
@entity900 :: (MESH:D002945,Chemical) :: ['Cisplatin']
